Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers

Abstract

The aim of the present study was to assess the interindividual variation in styrene toxicokinetics and to correlate this variation with the individual metabolic capacity for cytochromeP450 (CYP), CYP2E1, CYP1A2 and CYP2D6. Twenty male volunteers were exposed on separate occasions to 104±3 and 360 ± 20 mg/m³ of styrene for 1 h while performing 50 W physical exercise on a bicycle ergometer. Styrene concentrations in blood and mandelic (MA) and phenylglyoxylic acid (PGA) in urine were measured. The metabolic capacity was assessed by phenotyping with chlorzoxazone (CYP2El), caffeine (CYP1A2), dextromethorphan (CYP2D6) and antipyrine (CYP450). In addition, for the main styrene-metabolising enzyme, CYP2E1, genotyping for the genetic polymorphisms of the gene was performed. The average pulmonary retention of styrene was 62 ± 7% at both exposure concentrations, and the 24-h excretion of MA and PGA accounted for 58% of the dose at both concentrations. The interindividual variation in styrene kinetics ranged from 19% for the terminal half-life (t_1/2,β) of styrene to 41% for the cumulative excretion of MA and PGA. However, no correlation between the apparent blood clearance of styrene (CL_app), t_1/2,β of styrene or excretion of MA and PGA on one hand, and the individual metabolic capacity on the other hand was found. Although other explanations cannot be excluded, this lack of correlation might be due to the high apparent blood clearance (1.4 1/ min) of styrene, indicating that styrene metabolism is liver–blood-flow-dependent.

Keywords

styrene mandelic acid phenylglyoxylic acid cytochrome P450 interindividual variation

References

1 Sato A. The effect of environmental factors on the pharmacokinetic behaviour of organic solvent vapours . Ann Occup Hyg 1991; 35: 525-5541 .

2 Bond JA. Review of the toxicology of styrene . CRC Crit Rev Toxicol 1989; 19: 227-249 .

3 Wigaeus E , Lof A , Bjurstrom R , Byfalt Nordqvist M. Exposure to styrene. Uptake, distribution, metabolism and elimination in man . Scand J Work Environ Health 1983; 9: 479-488 .

4 Hallier E , Goergens HW , Karels H , Golka K. A note on individual differences in the urinary excretion of optical enantiomers of styrene metabolites and of styrenederived mercapturic acids in humans . Arch Toxicol 1995; 69: 300-305 .

5 Galassi S , Kogevinas M , Ferro G , Biocca M. Biological monitoring of styrene in the reinforced plastics industry in Emilia Romagna, Italy . Int Arch Occup Environ Health 1993; 65: 89-95 .

6 Guillemin MP , Berode M. Biological monitoring of styrene: a review . Am Ind HygAssocJ 1988; 49: 497-505 .

7 Wenker MAM , Kezic S , Monster AC , Wolff de FA. Metabolism of styrene–7,8–oxide in human liver in vitro: interindividual variation and stereochemistry . Toxicol Appl Pharmacol 2000; 169: 52-58 .

8 Guengerich FP , Turvy CG. Comparison of levels of several human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples . J Pharmacol Exp Ther 1991; 256: 1189-1194 .

9 Miller MS , McCarver DG , Bell DA , Eaton DL , Goldstein JA. Genetic polymorphisms in human drug metabolic enzymes . Fundam Appl Toxicol 1997; 40: 1-14 .

10.

10 Guengerich FP , Kim DH , Iwasaki M. Role of human cytochrome P450 IHEl in the oxidation of many low molecular weight cancer suspects . Chem Res Toxicol 1991; 4: 168-179 .

11.

11 Wenker MAM , Kezic S , Monster AC , Wolff de FA. Metabolism of styrene in human liver in vitro: interindividual variation and enantioselectivity. Xenobiotica 2001, in press.

12.

12 Nakajima M , Elovaara E , Gonzalez FJ , Gelbon HV , Vainio H , Aoyama T. Characterization of the human cytochrome P450 isoenzymes responsible for styrene metabolism . lARC Sci Publ 1993; 127: 101-108 .

13.

13 Hayashi S , Watanabe J , Kawajiri K. Genetic polymorphisms in the 5-flanking region change transcriptional regulation of the human cytochrome P450 IIEl gene . J Biochem 1991; 110: 559-565 .

14.

14 Girre C , Lucas D , Hispard E , Menez C , Dally S , Menez J. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics . Biochem Pharmacol 1994; 47: 1503-1508 .

15.

15 Kalow W , Tang BK. Use of caffeine metabolic ratios to explore CYP1A2 and xanthine oxidase activities . Clin Pharmacol Ther 1991; 50: 508-519 .

16.

16 Poulsen HE , Loft S. Antipyrine as a model drug to study hepatic drug-metabolizing capacity . J Hepatol 1988; 6: 374-382 .

17.

17 Hildesheim A , Chen C-J , Caporaso NE , Cheng Y-J , Hoover RN , Hsu M-M , Levine PH , Chen I-H , Chen J-Y , Yang CS , Daly AK , Idle JR. Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan . Cancer Epidemiol, Biomarkers Prev 1995; 4: 607-610 .

18.

18 Pirmohamed M , Kitteringham NR , Quest LJ , Allott RL , Green VJ , Gilmore IT , Park BK. Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians . Pharmacogenetics 1995; 5: 351-357 .

19.

19 KeOiM S , Jakasa I , Wenker MAM. Determination of mandelic acid enantiomers in urine by gas chromatography and electron capture or flame ionisation detection . J Chromatogr B 2000; 738: 39-46 .

20.

20 Frye RF , Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography . J Chromatogr 1996; 686: 291-296 .

21.

21 Dobrocky P , Bennett PN , Notarianni LJ. Rapid method for the routine determination of caffeine and its metabolites by high-performance liquid chromatography . J Chromatogr 1994; 652: 104-108 .

22.

22 Krul C , Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography . J Chromatogr B 1998; 709: 27-34 .

23.

23 Tang BK , Zubovits T , Kalow W. Determination of acetylated caffeine metabolites by high-performance exclusion chromatography . J Chromatogr 1986; 375: 170-173 .

24.

24 Ducharme J , Abdullah S , Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity . J Chromatogr 1996; 678: 113-128 .

25.

25 Opdam JJ. Respiratory input in inhalation experiments . Br J Ind Med 1989; 46: 145-156 .

26.

26 Jacqz-Aigrain E , Funck-Brentano C , Cresteil T. CYP2D6-and CYP3Adependent metabolism of dextromethorphan in humans . Pharmacogenetics 1993; 3: 197-204 .

27.

27 Dossing M , Poulsen HE , Andreasen PB , Tygstrup N. A simple method for determination of antipyrine clearance . Clin Pharmacol Ther 1982; 32: 392-396 .

28.

28 Astrand I , Kilbom A , Ovrum P , Wahlberg I , Vesterberg O . Exposure to styrene: I. Concentrations in alveolar air and blood at rest and during exercise and metabolism . Work Environ Health 1974; 11: 69-85 .

29.

29 Lof A , Lundgren E , Byfalt Nordqvist M. Kinetics of styrene in workers from a plastics industry after controlled exposure: a comparison with subjects not previously exposed . Br j Ind Med 1986; 43: 537-543 .

30.

30 Sedivec V , Flek J , Mraiz M. Urinary excretion of mandelic and phenylglyoxylic acids after human exposure to styrene vapour . J Hyg, Epidemiol, Microbiol Immunol 1984; 28: 241-255 .

31.

31 Tucker GT , Rostami-Hodjegan A , Jackson PR. Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues . Xenobiotica 1998; 28: 1255-1273 .

32.

32 Sumner SJ , Fennell TR. Review of the metabolic fate of styrene . Crit Rev Toxicol 1994; 24: S11-S33 .

33.

33 Ono S , Hatanaka T , Hotta H , Tsutsui M , Satoh T , Gonzalez FJ. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1 . Pharmacogenetics 1995; 5: 143-150 .

34.

34 Berthou F , Goasduff T , Lucas D , Dreano Y , Le Bot M , Menez J. Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans . Pharmacogenetics 1995; 5: 72-79 .

35.

35 Campbell ME , Spielberg SP , Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance . Clin Pharmacol Ther 1987; 42: 157-165 .

36.

36 Teunissen MW , Srivastava AK , Breimer DD. Influence of sex and oral contraceptive steroids on antipyrine metabolite formation . Clin Pharmacol Ther 1982; 32: 240-246 .

37.

37 Thomas RS , Bigelow PL , Keefe TJ , Yang RSH. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation . Am Ind HygAssoc J 1996; 57: 23-32 .